Targets › CA1
3 programs from 3 companies in 22 trials: 8 Phase 1, 7 Phase 4, 6 Phase 2, 1 Phase 3; Ophthalmology, Neurology, Cardiovascular; next expected readout Dec 2026.
Catalyzes the reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. (UniProt, P00915)
Open in Phaseline: the race on CA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Prisma Health-Upstate | Methocarbamol Carbonic anhydrase I inhibitor | CA1 | Phase 4 | Ventral Hernia | Jun 2027 |
| University of Colorado, Denver | Methazolamide Carbonic anhydrase VII inhibitor; Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor | CA7, CA1, CA2, CA4 | Phase 4 | Glaucoma, Open-Angle | – |
| Shionogi | Acetazolamide Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor; Carbonic anhydrase XII inhibitor | CA1, CA2, CA12, CA4 | Phase 2 | Sleep Apnea; Hypobaric Hypoxia; High Altitude Effects; Post Operative Pain … | Dec 2026 |
Sleep Apnea (3) Obstructive Sleep Apnea (3) Glaucoma, Open-Angle (1) Hypobaric Hypoxia (1) High Altitude Effects (1) Post Operative Pain (1) Sleep Disordered Breathing (1) Acute Heart Failure (1) Type 1 Diabetes (1) Acute Decompensated Heart Failure (1) Central Sleep Apnea Comorbid With Opioid Use (1) Malignant Glioma of Brain (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.